These findings highlight the tumor-suppressive role of PPP2R2C/B55γ in glioma, potentially pushing GBM cells into a therapeutic “dead-end,” limiting their ability to evade treatment. This evidence concerns the gene PPP2R2C and central nervous system cancer.